{
  "pmcid": "1876947",
  "sha256": "f0b6f41e8bb8ec78ace8c724351ef863c5bf5b76322f63fdf35a75fcced21f74",
  "timestamp_utc": "2025-11-09T23:43:51.371532+00:00",
  "model_used": "gpt-4o",
  "readability": {
    "flesch_kincaid": 12.555106241699868,
    "reading_ease": 29.88537295263393,
    "word_count": 251
  },
  "consort_scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "Title: Randomised Controlled Trial of Adjuvant Interferon Therapy in Hepatitis B-Related Hepatocellular Carcinoma"
      },
      "Trial_Design": {
        "score": 1,
        "evidence": "Randomisation was performed using a computer-generated sequence with allocation concealment."
      },
      "Participants": {
        "score": 2,
        "evidence": "patients with no residual disease after hepatic resection for predominantly hepatitis B-related HCC were enrolled from February 1999 to June 2002."
      },
      "Intervention": {
        "score": 2,
        "evidence": "randomly assigned to no treatment (control) or interferon alpha-2b 10 MIU/m² thrice weekly for 16 weeks (IFN-I group)."
      },
      "Objective": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "The primary outcome was overall survival, assessed at 1 and 5 years."
      },
      "Randomisation_Allocation": {
        "score": 2,
        "evidence": "Randomisation was performed using a computer-generated sequence with allocation concealment."
      },
      "Blinding": {
        "score": 0,
        "evidence": "Blinding was not implemented."
      },
      "Number_Randomised": {
        "score": 1,
        "evidence": "A total of 80 patients were randomised: 40 to the control group and 40 to the IFN-I group."
      },
      "Number_Analysed": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Result_Outcome": {
        "score": 3,
        "evidence": "The relative risk of death for interferon treatment was 0.42 (95% CI, 0.17–1.05; P = 0.063)."
      },
      "Harms": {
        "score": 1,
        "evidence": "Adverse effects led to discontinuation in the higher dose group."
      },
      "Trial_Registration": {
        "score": 0,
        "evidence": "Trial registration and funding details were not provided."
      },
      "Funding": {
        "score": 0,
        "evidence": "Trial registration and funding details were not provided."
      }
    },
    "total_score": 15,
    "max_score": 25
  }
}